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Uptake of Leishmania major by dendritic cells (DCs) results in activation and interleukin 
(IL)-12 release. Infected DCs effi  ciently stimulate CD4+ and CD8+ T cells and vaccinate 
against leishmaniasis. In contrast, complement receptor 3–dependent phagocytosis of 
L. major by macrophages (M𝖽) leads exclusively to MHC class II–restricted antigen presen-
tation to primed, but not naive, T cells, and no IL-12 production. Herein, we demonstrate 
that uptake of L. major by DCs required parasite-reactive immunoglobulin (Ig)G and in-
volved Fc𝗄RI and Fc𝗄RIII. In vivo, DC infi  ltration of L. major–infected skin lesions coincided 
with the appearance of antibodies in sera. Skin of infected B cell–defi  cient mice and 
Fc𝗄−/− mice contained fewer parasite-infected DCs in vivo. Infected B cell–defi  cient mice 
as well as Fc𝗄−/− mice (all on the C57BL/6 background) showed similarly increased disease 
susceptibility as assessed by lesion volumes and parasite burdens. The B cell–defi  cient mice 
displayed impaired T cell priming and dramatically reduced IFN-𝗄 production, and these 
defi  cits were normalized by infection with IgG-opsonized parasites. These data demonstrate 
that DC and M𝖽 use different receptors to recognize and ingest L. major with different 
outcomes, and indicate that B cell–derived, parasite-reactive IgG and DC Fc𝗄RI and Fc𝗄RIII 
are essential for optimal development of protective immunity.
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In cutaneous leishmaniasis aff  ecting mice and 
man, control of infection is associated with Th1/
Tc1-mediated, IFN-γ–dependent elimination 
of intracellular parasites (1, 2). After infection 
of mice with physiologic low dose inocula of 
Leishmania major parasites, the evolution of skin 
lesions occurs in three distinct phases (3). In the 
initial “silent” phase, resident macrophages (MΦ) 
phagocytose L. major promastigotes primarily via 
complement receptor 3 (CR3) (4, 5), which in-
activates the infected cells and allows parasite 
amplifi   cation (as intracellular amastigotes) at 
sites of infection. In the second phase, develop-
ment of clinically evident lesions occurs coinci-
dent with the infl   ux of infl   ammatory cells, 
including neutrophils, MΦ, and eosinophils. 
Subsequently, immunity is initiated by infi  ltra-
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tion of DCs as well as T and B cells, and lesions 
resolve (the third phase) (3).
Both MΦ and DCs, the major APCs in skin, 
clearly infl  uence the development of cellular im-
mune responses against Leishmania. Dermal MΦ 
capture organisms at sites of inoculation and, 
  after establishment of protective immunity, they 
ultimately kill the parasites. However, MΦ do 
not actively participate in T cell priming. In all 
likelihood, DCs take up amastigotes of L. major 
present in lesional skin, become activated, and 
migrate to draining LN where they present 
Leishmania antigen to naive T cells (6, 7). There 
are striking diff  erences in the ways that MΦ and 
DCs interact with L. major parasites in vitro. 
First, skin DCs preferentially take up L. major 
amastigotes, the obligate intracellular life form of 
the parasite, rather than promastigotes (trans-
mitted by sand fl  ies), whereas MΦ effi   ciently 178  FCR-MEDIATED UPTAKE OF L. MAJOR BY DENDRITIC CELLS | Woelbing et al.
phagocytose both life forms (7–9). Second, the phagocytotic 
capacity of DCs is limited with regard to effi   ciency and capacity 
as compared with that of MΦ (7). Third, L. major–infected 
DCs, unlike infected MΦ, release IL-12 and effi   ciently induce 
Th1/Tc1 diff  erentiation of naive cells (7, 10–12). Fourth, al-
though both cell types present Leishmania antigen via the MHC 
class II pathway, only DCs prime and restimulate L. major–  specifi  c 
CD8+ T cells (13).
Based on the diff  erent behaviors and functional roles of 
MΦ and DCs in L. major infections, we hypothesized that 
DCs and MΦ might take up L. major via diff  erent phagocy-
totic receptors. MΦ ingest L. major via CR3-dependent 
mechanisms (4). Herein, we identifi  ed immune IgG and Fcγ 
receptors (FcγRI and FcγRIII) as critical mediators of L. 
  major uptake by DCs in vitro. In vivo, mice infected with 
IgG-opsonized parasites showed enhanced protective immu-
nity as well as increased numbers of L. major–infected lesional 
DCs. We also determined that B cell– (μMT and JHT) and 
Fcγ-defi  cient mice had decreased numbers of L. major–in-
fected lesional DCs and enhanced lesion progression. In ad-
dition, we observed impaired CD4- and CD8-priming in the 
absence of B cells. Immune IgG production and engagement 
of DC FcγR are required for timely development of Th1/
Tc1-dependent immunity and control of experimental cuta-
neous leishmaniasis in mice.
RESULTS
CR3 does not mediate uptake of L. major by DCs
MΦ phagocytosis of L. major promastigotes and amastigotes is 
rapid and effi   cient (1). In contrast, skin DCs preferentially 
  ingest amastigotes, and this occurs slowly and ineffi   ciently 
(7). We generated bone marrow–derived DCs (BMDCs) us-
ing GM-CSF/IL-4 and confi  rmed our previous fi  ndings ob-
tained with skin DCs. Day 6 immature DCs expressed 
CD11c, intermediate levels of MHC class II, and low levels 
of CD86 (Fig. 1 A). BMDCs, like skin DCs, internalized 
freshly isolated amastigotes in a time- and dose-dependent 
manner. Normal mouse serum (NMS)-opsonized promasti-
gotes, in contrast, were not readily ingested (27 ± 6 vs. 8 ± 1% 
infected DCs with a DC/parasite ratio of 1:3 at 18 h; P ≤ 
0.05, Fig. 1 B). As expected, DC infection was associated with 
up-regulation of MHC class I/II and costimulatory markers 
(reference 7 and unpublished data).
Phagocytosis of L. major by MΦ is CR3 dependent (5). 
To investigate the role of CR3 and CR4 in L. major uptake 
by DCs, we used CD18−/− mice. As expected, DCs gener-
ated from CD18−/− mice did not express CD11b or CD11c 
(unpublished data). No diff  erences in the percentages of in-
fected wild type or CD18−/− DCs (Fig. 1 C) or the number 
of parasites/cell was observed after DCs and L. major amasti-
gotes were cocultured for 18 h.
We also assessed the involvement of other candidate re-
ceptors. Antibodies reactive with CD11b (clone M1/70) (9), 
CD205 (clone NLDC145) (14), or preincubation with man-
nan (5) were used at optimal concentrations. This concentra-
tion of mannan was able to completely inhibit the uptake of 
C. albicans by MΦ (unpublished data) (5). None of the inhib-
itors tested aff  ected the uptake of L. major by DCs (Fig. 1 D). 
Thus, CR3/CR4 and C-type lectins appear to be dispensable 
for phagocytosis of L. major by DCs.
Immunoglobulins enhance uptake of L. major by DCs
L. major amastigotes are isolated from infected tissues, whereas 
metacyclic promastigotes are enriched from stationary phase 
in vitro cultures. Among the most prominent diff  erences be-
tween surface characteristics is the large amount of Ig bound 
Figure 1.  L. major amastigotes, rather than promastigotes, are 
preferentially internalized by DCs independent from CR3/CR4. Bone 
marrow–derived DCs and amastigotes or promastigotes of L. major were 
cocultured at various ratios at 2 × 105 DCs/ml. (A) Before coculture, sur-
face phenotypes of immature DCs were verifi  ed by FACS. (B) At the indi-
cated time points, cells were harvested, cytospun, and the percentage 
of infected cells was determined (mean ± SEM, n ≥ 3, *, P ≤ 0.05, 
**, P ≤ 0.005, ***, P ≤ 0.002). (C) DCs from CD18−/− and wild-type 129 × 
C57BL/6 controls were cocultured with L. major (1:3). (D) C57BL/6 DC were 
preincubated with 5 mg/ml mannan, 50 μg/ml anti-CD11b, anti-DEC205, 
or isotype control before amastigotes of L. major were added (1:3). 
(C and D) After 18 h, cells were harvested and cytospins were analyzed 
for the percentage of infected DC (mean ± SEM, n ≥ 3, *, P ≤ 0.05).JEM VOL. 203, January 23, 2006  179
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to the surfaces of amastigotes, but not promastigotes. To deter-
mine if Ig was involved in parasite uptake, we quantifi  ed the 
ability of amastigotes isolated from B cell–replete, wild-type 
BALB/c mice, μMT (B cell–defi  cient) mice and SCID (B 
cell– and T cell–defi  cient) mice to parasitize DCs. DCs readily 
phagocytosed amastigotes from BALB/c mice, but not amasti-
gotes from μMT or SCID mice (Fig. 2, A and B). Opsoniza-
tion with NMS did not aff   ect uptake. Parasites from B 
cell–defi  cient mice effi   ciently entered DCs only after they had 
been preincubated with Ig-containing immune serum (IS) from 
L. major–infected BALB/c mice (or C57BL/6 mice; unpub-
lished data). Phagocytosis of amastigotes by MΦ was not af-
fected by the presence or absence of Ig. Opsonization of 
amastigotes from B cell–defi  cient mice with IS (Fig. 2 C) also 
induced enhanced release of IL-12p40 from DCs, whereas in-
fection of MΦ did not promote IL-12 production. Ig-mediated 
uptake of amastigotes did induce IL-10 release from MΦ (15), 
whereas little, if any, IL-10 was produced by infected DCs.
To determine if Ig-coated promastigotes could be in-
gested by DCs, metacyclic L. major promastigotes were left 
untreated or were opsonized with NMS or IS for 10 min at 
37°C. After washing, parasites were cocultured with DCs for 
18 h. IS-treated promastigotes were effi   ciently taken up by 
DCs and induced IL-12 release, whereas untreated or NMS-
treated parasites were not ingested (Fig. 3 A). Interestingly, 
complete transformation of promastigotes into amastigotes 
was not observed within all DCs, even after 18 h (Fig. 3 B), 
suggesting that there are diff  erences in the phagosomal com-
partments of DCs and MΦ that infl  uence this transition (e.g., 
diff   erences in pH, content of proteolytic enzymes) (16). 
Stimulation of antigen-specifi  c, carboxyl fl  uorescein succin-
imidyl ester (CFSE)-labeled T cells with parasite-treated DCs 
revealed that DCs infected with NMS amastigotes or IS pro-
mastigotes induced similar expansion of both CD4+ and 
CD8+ T cells, whereas DCs treated with NMS promastigotes 
did not promote T cell proliferation (Fig. 3 C).
Phagocytosis of L. major is IgG dependent
Amastigotes from infected tissue effi   ciently parasitize DCs. 
By fl  ow cytometry, we detected both IgG1 and IgG2a/b on 
the surfaces of amastigotes when analyzed directly after isola-
tion from C57BL/6 mice or after opsonization with NMS 
(Fig. 3 D). Additional opsonization with NMS or IS led to 
enhanced binding of IgM to amastigotes. Cell surface Ig was 
not detected on promastigotes. NMS-opsonized promasti-
gotes exhibited surface-associated IgM, attributable to natural 
Ig found in the sera of naive mice (17). Because both NMS- 
and IS-opsonized amastigotes were taken up to similar   extents 
and NMS-opsonized promastigotes were not phagocytosed 
by DCs (compare with Fig. 3 A), we conclude that IgM is 
not required for parasite uptake. Interestingly, promastigotes 
bound similar amounts of IgG1 and IgG2a/b when incubated 
with sera harvested from infected resistant C57BL/6 mice 
(Fig. 3 D) or susceptible BALB/c mice (unpublished data).
To conclusively implicate immune IgG in DC-parasite 
uptake, we isolated total IgG from IS using protein G affi   nity 
columns and tested the capacity of IgG to trigger phagocyto-
sis. Similar to IS, the IgG fraction mediated uptake of pro-
mastigotes, whereas parasites incubated with the IgG-depleted 
fraction were not phagocytosed (Fig. 3 E). In addition, para-
site uptake was associated with IL-12p40 release (772 ± 324 
pg/ml for DCs incubated with IgG promastigotes vs. 137 ± 
27 pg/ml for DCs cocultured with promastigotes incubated 
with the IgGneg fraction; n ≥ 3, P = 0.03).
Figure 2.  Immunoglobulins are required for internalization of 
L. major amastigotes by DCs. Amastigotes of L. major were prepared 
from BALB/c mice or mice defi  cient for B cells (μMT or SCID mice). 
As indicated, parasites were opsonized for 10 min with 5% of normal 
mouse serum (NMS) or serum from 6 wk L. major–infected BALB/c mice 
(IS) and added to DCs or skin-MΦ from C57BL/6 mice (2 × 105 cells/ml) 
at a parasite/cell ratio of 3:1. (A and B) 18 h later, cells were harvested 
and cytospun and the percentage of infected cells was determined by 
light microscopy and expressed as mean ± SEM (n ≥ 4, *, P ≤ 0.05,
 ***, P ≤ 0.002). (C) The coculture supernatants were assayed for the pres-
ence of IL-12p40 and IL-10 by ELISA (mean ± SEM, n ≥ 4).180  FCR-MEDIATED UPTAKE OF L. MAJOR BY DENDRITIC CELLS | Woelbing et al.
Figure 3.  Infectious stage promastigotes of L. major infect DCs in 
the presence of IgG. DCs were cocultured with metacyclic promastigotes 
of L. major that had either been left untreated or were opsonized with nor-
mal mouse serum (NMS) or serum of 6 wk–infected BALB/c mice (IS) before 
addition to the cultures. (A and B) Cells were harvested after 18 h and in-
fection rates were determined on cytospins. The IL-12p40 production of 
DCs was analyzed by ELISA (mean ± SEM, n = 3, *, P ≤ 0.05; **, P ≤ 0.005). 
(C) BMDCs infected as indicated were coincubated (1:2) with CFSE-labeled 
LN cells (at 106 cells/200 μl) obtained from 6 wk–infected C57BL/6 mice. 
Antigen-specifi  c expansion of CD4+ and CD8+ T cells was assessed and the 
relative number of Leishmania-reactive cells (in percents of total CD4+ or 
CD8+ T cells) was determined in DC-stimulated cultures compared with 
untreated control cultures. One representative FACS result is shown on the 
left, pooled data is shown on the right (mean ± SEM, n = 3, *, P ≤ 0.05). 
Both Fc𝗄RI and Fc𝗄RIII mediate uptake of L. major by DCs
IgG1-containing immune complexes bind preferentially to 
FcγRIII (and FcγRII) and IgG2a-containing complexes bind 
with higher affi   nity to FcγRI than to FcγRIII. FcγRII typi-
cally mediates endocytosis of soluble immune complexes 
(18). DCs from knockout mice defi  cient for single FcγR 
family members ingested L. major as effi   ciently as DCs from 
wild-type mice (Fig. 4 A). In addition, blocking antibodies 
directed against FcγRII/III (clone 2.4G2) did not have a dra-
matic eff  ect on L. major uptake by wild-type DCs (Fig. 4 B, 
left). However, signifi  cant inhibition of L. major phagocytosis 
by DCs (up to 70%) was observed if DCs from FcγRI/III- or 
Fcγ-defi  cient mice were compared with wild-type cells (Fig. 
4 B). Uptake of amastigotes and Ig-opsonized promastigotes 
was impaired to similar extents. Thus, FcγRI and FcγRIII 
each facilitate phagocytosis of L. major by DCs, and these re-
ceptors can compensate for one another.
Accumulation of infected DCs in lesions coincides 
with the appearance of Leishmania-specifi  c IgG in sera
In the setting of physiologic low dose infections, we have 
shown that increased accumulation of both T cells and DCs at 
inoculation sites coincides with the onset of lesion involution 
(3). In addition, infi  ltration with DCs was delayed as com-
pared with MΦ recruitment and infection. DCs were identi-
fi  ed in lesions beginning 5 wk after inoculation, and their 
number increased substantially during the healing phase.
To determine if immune IgG, which dramatically en-
hances L. major infection of DCs in vitro, is present at the 
time that DCs are recruited to Leishmania lesions, we infected 
C57BL/6 mice with 103 promastigotes and quantifi  ed the 
number of infl  ammatory cells in lesional skin as well as the 
appearance of Leishmania-reactive IgG in sera at weekly in-
tervals. Fig. 5 shows that by weeks 5–6 after infection, the 
numbers of DCs as well as serum parasite-specifi  c IgG levels 
were increased. This indicates that Leishmania-specifi  c IgG is 
available to opsonize parasites and enhance phagocytosis by 
DCs at the time that DCs are infected in vivo. Signifi  cant 
  accumulation of CD19+ B cells in lesional skin (>103 cells) 
was not detected within 8 wk after infection.
In vivo targeting of DCs with IgG-opsonized promastigotes 
speeds disease resolution
Previously, we and others have demonstrated that L. major–
infected DCs release IL-12 and eff  ectively vaccinate against 
(D) Parasites were analyzed for surface binding of Ig subclasses after dif-
ferent opsonization procedures. Amastigotes were isolated from infected 
C57BL/6 tissue and opsonized. Promastigotes were enriched from station-
ary phase cultures and opsonized similarly. One out of three independent 
experiments with similar results is shown. (E) IgG was purifi  ed from IS. 
IgG as well as the IgGneg fraction were used for opsonization of promasti-
gotes. Opsonized promastigote preparations were cocultured with DCs for 
18 h at a ratio of 3:1 (2 × 105 cells/ml). Cells were harvested and the 
percentage of infected cells was determined on cytospins (mean ± SEM, 
n = 3, *, P ≤ 0.05).JEM VOL. 203, January 23, 2006  181
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progressive disease (10–12). Therefore, infection of DCs in 
vivo earlier in the course of infection should accelerate devel-
opment of Th1 immunity. To test this hypothesis, promasti-
gotes were opsonized either with NMS or IS. After washing, 
low dose infections using 103 opsonized parasites were initi-
ated in the ear skin of C57BL/6 mice (Fig. 6). Infl  ammatory 
dermal cells from lesional ear skin were studied weekly (Fig. 
6, A and B). Interestingly, the numbers of CD11c+ DCs in IS 
promastigote–infected skin were signifi  cantly higher (7.9 ± 
0.9 × 104/lesion) than those in NMS promastigote–treated 
ears (2.5 ± 0.5 × 104/lesion in week 1, n = 3, P ≤ 0.005), 
especially at early time points. At later time points (week 3 
and after), this diff  erence was not evident. DCs were en-
riched by preparative fl  ow sorting and the number of infected 
DCs was determined (Fig. 6, B and C). At early time points, 
the percentage of DCs containing intracellular amastigotes 
was low. However, by week 2, signifi  cantly more infected 
cells were found in ears of mice infected with IS- versus 
NMS-opsonized parasites (9.5 ± 1.3 vs. 3.4 ± 0.7%, n = 3, 
P ≤ 0.002). By week 3, this diff  erence also disappeared.
Lesion development in infected mice was monitored for 
>3 mo. Interestingly, cutaneous lesions of mice infected with 
IS-opsonized parasites were signifi  cantly smaller and resolved 
more quickly than those in mice that were infected with par-
asites opsonized with NMS (Fig. 6 D). In addition, lesional 
parasite loads were decreased in weeks 4 and 6 after infection 
in mice inoculated with IS-opsonized parasites compared 
with NMS-treated parasites (Fig. 6 E). Smaller lesion vol-
umes were associated with increased Th1 immunity as mea-
sured by antigen-specifi  c restimulation of LN cells at weeks 4 
and 6 (Fig. 6 F). The IFN-γ/IL-4 ratio in IgG-parasite in-
fected mice was Th1-predominant (week 6: 1,068 ± 250) as 
compared with mice infected with NMS-opsonized parasites 
(week 6: 382 ± 86, n = 6, P ≤ 0.05). Collectively, these data 
suggest that enhanced IgG-mediated recruitment and L. major 
infection of DCs in vivo leads to enhanced Th1 immunity 
and more rapid resolution of cutaneous lesions.
B cell–defi  cient mice show enhanced lesion progression 
associated with decreased numbers of infected DCs 
and impaired CD4- and CD8-priming
Because our data suggested that IgG mediates parasite uptake 
by DCs, we characterized L. major infections in B cell–defi  -
cient μMT mice (19). Herein, wild-type C57BL/6 or μMT 
mice were infected with physiologically relevant doses of 
L. major (103 promastigotes). Compared with wild-type mice, 
μMT mice showed signifi  cantly enhanced lesion progression 
from week 6 after infection (Fig. 7 A). Lesion involution was 
delayed by  4 wk in μMT compared with control mice. 
Furthermore, the skin of μMT mice contained greater num-
bers of parasites reaching a peak load of 4 ± 2 × 105 para-
sites/ear at week 6 as compared with 3 ± 2 × 104 parasites/ear 
in wild types (P ≤ 0.05) (Fig. 7 B). The IFN-γ/IL-4 ratios of 
μMT LN cell cultures stimulated with soluble Leishmania an-
tigen (SLA) were also skewed toward a Th2 profi  le as com-
pared with C57BL/6 cells. In weeks 6 and 8 after infection, 
μMT LN cells released signifi  cantly less IFN-γ and more IL-4 
compared with C57BL/6 mice (e.g., 40.1 ± 12.6 in μMT 
compared with 100.7 ± 19.2 ng IFN-γ/ml in C57BL/6 
mice in week 6, n ≥ 9, P ≤ 0.05; Fig. 7 C).
Figure 4.  Fc RI/III mediate uptake of L. major parasites by DCs. 
Bone marrow–derived DCs from C57BL/6, FcγRII−/−, FcγRI−/−, FcγRIII−/−, 
Fcγ−/−, and FcγRI/III−/− were cocultured with L. major at a ratio of 1:3 
(2 × 105 cells/ml). Parasites (Am = amastigotes, Prom = promastigotes) 
were opsonized with normal mouse serum (NMS) or serum of 6 wk–  infected 
BALB/c mice (IS) for 10 min before addition to the cultures. As indicated, 
50 μg/ml anti-CD16/32 (clone 2.4G2) or isotype control was added to the cells 
1 h before the parasites (B). Cells were harvested after 18 h. The percentage of 
infected cells was determined (mean ± SEM, n ≥ 3, *, P ≤ 0.05, **, P ≤ 0.005 
compared with isotype treatment [B, left] or wild type control [B, right]).
Figure 5.  The appearance of parasite-specifi  c IgG is coincident 
with DCs recruitment into Leishmania lesions. Accumulation of DCs 
into skin lesions of L. major–infected C57BL/6 mice (103 metacyclic pro-
mastigotes intradermally, day 0) was determined as described previously. 
In parallel, the anti-Leishmania antibody response was monitored in the 
serum by ELISA (mean ± SEM, n = 5 mice). One out of two independent 
experiments with similar results is shown.182  FCR-MEDIATED UPTAKE OF L. MAJOR BY DENDRITIC CELLS | Woelbing et al.
Figure 6.  Increased recruitment and infection of DCs after injec-
tion of IgG-opsonized promastigotes of L. major leads to enhanced 
protection in vivo. C57BL/6 mice were infected intradermally into ear 
skin with 103 metacyclic promastigotes that have been opsonized with 
normal mouse serum (NMS) or serum from 6 wk–infected BALB/c mice 
(IS) and washed. Infl  ammatory ear cells were isolated and analyzed for 
the presence of CD11c+ DCs at different time points by fl  ow cytometry 
(A). The number of DCs per ear was calculated (mean ± SEM, n = 3, 
**, P ≤ 0.005; B). CD11c+ DCs were purifi  ed using fl  ow sorting and cytos-
pun. The percentage of infected DCs was determined by light microscopy 
(mean ± SEM, n = 3, ***, P ≤ 0.002; B and C). (D) Lesion development 
was monitored over the course of >3 mo. Lesion volumes are shown as 
mean ± SEM (**, P ≤ 0.005 and ***, P ≤ 0.002, n ≥ 10 mice). (E) Parasite 
loads of infected mice were determined at the indicated time points using 
limiting dilution assays. Each data point represents the number of orga-
nisms from one ear and the bars indicate arithmetic means. One repre-
We also isolated infl  ammatory cells from infected ears 
of μMT and wild-type mice. No signifi  cant diff  erence in 
the number of CD11c+ DCs that accumulated in the le-
sions of μMT mice as compared with C57BL/6 ears was 
found (unpublished data). However, lesions of μMT mice 
contained signifi  cantly fewer L. major–infected DCs at sev-
eral time points (Fig. 7 D). Finally, we sought to determine 
if there was a correlation between numbers of infected 
DCs and the ability to prime CD4 and CD8 T cells in situ. 
LN cells of infected C57BL/6 or μMT mice were isolated 
6 wk after infection and labeled with CFSE. Antigen-spe-
cifi  c expansion of CD4+ and CD8+ T cells was assessed 
5 d after restimulation of LN cells with SLA. μMT LN 
cells exhibited decreased SLA-specifi  c CD4 expansion as 
compared with C57BL/6 cells (3.7 ± 1% vs. 15.7 ± 3%; 
Fig. 7, E and F). Interestingly, the number of Leishmania-
reactive CD8+ T cells was also greatly reduced in the ab-
sence of B cells (SLA: 2.9 ± 0.5% compared with 14.1 ± 
3.9% in C57BL/6 mice, n = 5, P ≤ 0.05). In summary, 
enhanced lesion progression in the μMT mice was associ-
ated with decreased numbers of infected DCs and defective 
T cell priming.
Infection of 𝗍MT mice with IgG-opsonized parasites 
normalizes lesion development
To investigate whether the defi  ciency in B cells or the lack 
of antibody contributed to the phenotype of μMT mice, we 
infected μMT mice with 103 NMS- or IS-opsonized pro-
mastigotes. In this setting, μMT mice infected with L. major 
developed lesions in the presence of immune IgG that were 
signifi  cantly smaller than those caused by NMS-opsonized 
parasites (Fig. 8 A). In parallel, decreased lesion volumes in 
IgG-opsonized parasite-infected μMT mice correlated with 
signifi  cantly smaller parasite burdens in week 6 (Fig. 8 B). In 
IS parasite–infected μMT mice, the IFNγ/IL-4 ratio was 
shifted from a Th2-predominant (828 ± 94) to a Th1 im-
mune response (3,680 ± 1,515, n = 4, week 6). Thus, the 
lack of host IgG is responsible for disease outcome in μMT 
mice. The skin of μMT mice infected with NMS-opsonized 
or IS-opsonized promastigotes was analyzed for the presence 
of infected CD11c+ DC (Fig. 8 C). As shown before, in-
fection of maximally 5% of DCs was found in μMT mice 
infected with NMS-treated parasites. Interestingly, inocula-
tion of IgG-containing parasites led to dramatically increased 
numbers of infected DCs in the early course of infection (Fig. 
8 C), even higher than those found in wild types (compare 
with Fig. 7 D).
The μMT mice were previously shown to contain Ig 
in the sera, at least when mice were of BALB/c genetic 
  background (20, 21). The presence of soluble Ig is due 
to low-level leakiness of the locus (21). To confi  rm critical 
sentative out of two independent experiments is shown. (F) Cytokine 
levels were determined in LN cultures stimulated in the presence of solu-
ble Leishmania antigen by ELISA (mean ± SEM, *, P ≤ 0.05, n ≥ 10).JEM VOL. 203, January 23, 2006  183
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experiments in a truly B cell–defi   cient mouse strain, we 
  infected C57BL/6 JHT mice characterized by deletion of the 
Ig heavy chain (22). As shown in Fig. 8 D, increased lesion 
development was observed in JHT mice over the course of 
4 wk identical to the course of infections in μMT mice. This 
is in contrast with the fi  ndings of Miles et al., who reported 
that JH mice on a BALB/c background were less susceptible 
to infection than their controls (23).
Figure 7.  Increased lesion progression in μMT mice due to de-
creased numbers of L. major–infected lesional DC and impaired 
T cell priming. Groups of ≥5 C57BL/6 or B cell–defi  cient μMT mice were 
infected into ear skin with 103 metacyclic promastigotes. (A) Lesion de-
velopment was monitored over the course of >3 mo (mean ± SEM, 
*, P ≤ 0.05, **, P ≤ 0.005, and ***, P ≤ 0.002, n ≥ 3). (B) Lesional parasite 
loads were determined; bars indicate arithmetic means. Pooled data of 
two to three experiments are shown. (C) LN cells were harvested and anti-
gen-specifi  c cytokine release was determined after 48 h using ELISA 
 specifi  c for murine IFN-γ and IL-4 (mean ± SEM, n ≥ 5, *, P ≤ 0.05). 
(D) Infl  ammatory ear cells were isolated and CD11c+ DCs were purifi  ed 
using fl  ow sorting. The percentage of infected DCs was determined on 
cytospins (mean ± SEM, n = 3, *, P ≤ 0.05). (E and F) Antigen-specifi  c 
proliferation of CD4+ and CD8+ T cells was determined in week 6 after 
infections. LN cells were labeled with CFSE and subcultured in the pres-
ence of soluble Leishmania antigen (SLA). T cells were pregated using 
staining for CD4 or CD8. For each mouse, the relative number of Leishma-
nia-reactive cells (in percentage of total CD4+ or CD8+ T cells) was calcu-
lated in antigen-stimulated compared with untreated control cultures 
(mean ± SEM, n = 2, *, P ≤ 0.05).
Figure 8.  Normalization of cutaneous leishmaniasis in B cell–
defi  cient μMT infected with IgG-opsonized promastigotes of 
L. major. Groups of ≥5 μMT mice were infected into ear skin with 
103 NMS- or IS-opsonized metacyclic promastigotes. (A) Lesion volumes 
are presented as mean ± SEM (n = 3, *, P ≤ 0.05, and ***, P ≤ 0.002). 
(B) Parasite loads of infected ears were determined in week 6 after infec-
tion using limiting dilution assays. Each data point represents the num-
ber of organisms from one ear and bars indicate arithmetic means. One 
representative out of two independent experiments is shown. (C) Lesional 
CD11c+ DCs were purifi  ed using fl  ow sorting at the indicated time 
points and the percentage of infected DCs was determined on cytospins 
(mean ± SEM, n = 2, *, P ≤ 0.05). (D) B cell–defi  cient JHT mice were in-
fected with 103 metacyclic promastigotes and developing lesions moni-
tored every week (mean ± SEM, *, P ≤ 0.05, and ***, P ≤ 0.002, n ≥ 10 
mice/group). (E) Groups of ≥5 C57BL/6 Fcγ−/− mice were infected with 
103 metacyclic promastigotes. Lesion volumes were assessed for >3 mo 
and are presented as mean ± SEM (*, P ≤ 0.05 and ***, P ≤ 0.002, n = 2). 
Parasite loads were determined in week 4 by limiting dilution assay. One 
representative out of two independent experiments is shown 
(*, P ≤ 0.05). The number of infected lesional DCs was determined on 
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Enhanced lesion progression and decreased numbers 
of infected DCs in vivo in mice lacking Fc receptors
Our data suggested that FcγR-mediated uptake of L. major 
parasites by DCs mediates protection. Thus, we infected Fcγ 
chain–defi  cient mice lacking all three known activating FcR 
with physiologically low dose inocula of L. major (Fig. 8 E). 
Lesions were monitored for >3 mo. Fcγ−/− C57BL/6 mice 
developed more progressive lesions between weeks 4 and 9 as 
compared with wild-type controls. Maximum lesion sizes in 
Fcγ−/− mice were detected in week 9, reaching 21 ± 2 mm3 
(C57BL/6: 13 ± 1 mm3, n = 14, P ≤ 0.008). Increased le-
sion volumes were paralleled by signifi  cantly higher parasite 
burdens as determined in week 4 after infection (Fig. 8 E). 
Similar to the course of disease in B cell–defi  cient mice, le-
sion involution in Fcγ−/− mice was normal and all mice 
  ultimately healed their infection. This data suggests that FcR-
mediated antibody eff  ects are not an absolute requirement 
for healing.
Finally, we assessed the number of parasite-containing 
CD11c+ DC in lesions of Fcγ−/− mice infected for 4 wk 
with low doses of L. major (Fig. 8 E). Ear skin of FcR-defi  -
cient mice harbored fewer parasite-infected DC (10.5 ± 
2.3%) as compared with wild-type DCs (20.2 ± 3.8%, n = 4, 
P = 0.09). This fi  nding confi  rmed our in vitro data ob-
tained with BMDCs generated from Fcγ−/− mice that 
demonstrated inhibited parasite uptake in cocultures with 
L. major (Fig. 4 B).
D  I  S  C  U  S  S  I  O  N 
Microbe-binding receptors orchestrate events that occur sub-
sequent to phagocytosis by transducing specifi  c cellular signals 
(24). The main receptor for uptake of Leishmania promasti-
gotes by MΦ is CR3 (4, 5). In the initial stages of cutaneous 
leishmaniasis, most parasites are taken up by MΦ. CR3-me-
diated phagocytosis of Leishmania by MΦ leads to selective 
inhibition of IL-12 release (5, 25–27). Production of IL-12 in 
leishmaniasis is delayed (3), and we and others have suggested 
that DCs, rather than MΦ, are the primary source of this 
Th1-promoting cytokine. It has also been demonstrated that 
infected DCs are activated and eff  ectively present L. major 
antigen to both naive CD4+ and CD8+ T cells in vitro and 
vaccinate against leishmaniasis in vivo (7, 10, 12, 13).
Although MΦ and DCs are ontogenically related, their 
roles in initiation and propagation of immune responses against 
L. major are distinctly diff  erent. Uptake of L. major by DCs 
diff  ered signifi  cantly from that by MΦ with regard to kinetics 
as well as effi   ciency. Therefore, we speculated that phagocy-
tosis of parasites by DCs might be promoted by receptors 
other than CR3. However, a previous report suggested that 
uptake of L. major amastigotes by Langerhans cells/DCs was 
mediated via CR3 (9). In the present study, using both block-
ing antibodies as well as cells defi  cient for CR3 and CR4 
(from CD18−/− mice), we were not able to detect CR3-me-
diated uptake of L. major by DCs. Recently, C-type lectins 
(DC-SIGN, DEC-205, and Dectin-1) have also been impli-
cated in the uptake of various pathogens by DCs (14, 28–31). 
We were unable to implicate mannan-binding C-type lectins 
in phagocytosis of L. major by murine DCs.
In this study, we demonstrate that L. major parasites are 
predominantly phagocytosed by DCs via FcγRI and FcγRIII. 
In line with several studies, FcγR ligation was associated with 
DC activation and IL-12 release (32–34). We have previ-
ously shown that DCs can cross-present Leishmania antigen 
to CD8+ T cells (13), whereas CR3-mediated phagocytosis 
by MΦ leads exclusively to MHC class II–restricted antigen 
presentation. These results bear some similarity to experi-
ments evaluating the role of FcγR in antitumor immunity. In 
Fcγ−/− mice, eff  ective cross-presentation of tumor antigens 
by DCs was also dependent on FcγR-dependent activation 
(35). In addition, signaling through FcγRI/III facilitated 
  effi   cient restimulation of tumor-reactive T cells (36). Thus, 
cross-presentation of both tumor-derived and L. major–asso-
ciated antigens by DCs requires FcγR, and is presumably de-
pendent on production of specifi  c antibody as well.
In MΦ, ingestion of amastigotes, in contrast with CR3-
phagocytosed promastigotes, appears to occur through both 
the FcγR and CR3 (15, 37). In our work and consistent with 
prior fi  ndings, IgG did not play an important role in the up-
take of amastigotes from SCID versus BALB/c mice by 
  infl  ammatory skin MΦ (38). Our results also confi  rm the 
fi  nding that IgG-mediated phagocytosis of L. major by MΦ 
leads to strong release of IL-10, and no IL-12 synthesis (15), 
which might promote parasite survival (39). Thus, FcγR-
mediated uptake by MΦ and DCs has opposing roles in initi-
ating immune responses in cutaneous leishmaniasis.
The role of B cell–derived IgG in cutaneous leishmania-
sis in vivo is not fully understood yet. Polyclonal activation 
of human B cells leads to the production of large amounts 
of parasite-specifi  c and nonspecifi  c Ab, particularly IgM and 
IgG (40). Also, amastigotes released into lesional tissue from 
infected and lysed MΦ appear to be coated with antiparasite 
antibodies (41). In this study, we show that Leishmania-spe-
cifi  c IgG was present in sera at the time of DC accumula-
tion in lesions. Consistent with prior fi  ndings, intradermal 
infection with IgG-opsonized parasites led to enhanced 
early recruitment of CD11c+ DCs into the lesions (38), 
most likely by IgG-triggered chemokine release from MΦ 
(42, 43). Administration of IgG-opsonized parasites also led 
to enhanced infection of DC, augmented T cell priming, 
and limited disease as compared with inoculation of IgG-
free parasites.
Prior data and our experiments suggest that IgG-medi-
ated eff  ects diff  er signifi  cantly, dependent on the genetic 
background of the mice. B cell–defi  cient JH BALB/c mice 
showed improved disease outcome after infection with sup-
raphysiologic doses of L. pifanoi and coinjection of anti-Leish-
mania IgG reversed their phenotype (44). Administration of 
IgG at or near the time of parasite inoculation worsened dis-
ease outcome in BALB/c mice (40, 45, 46). This is consistent 
with studies demonstrating that FcγR ligation on infected 
MΦ induced IL-10 release, which in turn prevented parasite 
elimination and promoted disease progression (15, 23). Final JEM VOL. 203, January 23, 2006  185
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proof was provided by the demonstration that anti-  Leishmania 
IgG reconstitution of JH BALB/c mice correlated with in-
creased IL-10 production and blocking of IL-10R prevented 
antibody-mediated disease exacerbation (23).
Mice on a Leishmania-resistant background lacking func-
tional B cells (e.g., μMT C57BL/6 mice) did not exhibit a 
phenotype with regard to lesion development after high dose 
infection with L. major (19, 37, 47, 48). However, DeKrey 
et al. reported that C57BL/6 μMT mice infected with high-
dose inocula of L. major showed reduced IFN-γ production 
after pathogen challenge (48). In our experiment, using phys-
iologically relevant low dose inocula, μMT as well as JHT 
C57BL/6 mice consistently exhibited enhanced lesion pro-
gression and delayed lesion involution, higher parasite loads, 
and cytokine profi  les consistent with a Th2-predominant im-
mune response as compared with C57BL/6 mice. In accor-
dance with our in vitro data, signifi  cantly fewer infected DCs 
were found in lesions of μMT mice. In addition, we deter-
mined that in the absence of Leishmania IgG-mediated infec-
tion of DCs, decreased numbers of Leishmania-reactive CD4+ 
and CD8+ T cells developed. The defects observed in μMT 
mice were reversed by using IgG-opsonized parasites for in-
fection indicating that the defi  ciency in Ig is responsible for 
worsened disease outcome in B cell–defi  cient mice.
As expected from the in vitro results obtained with BM-
DCs generated from Fcγ-defi  cient mice, we also found de-
creased numbers of infected DC in Fcγ−/− mice paralleled 
by increased lesion volumes over the course of several weeks 
and higher parasite burdens. In contrast, in prior studies, im-
proved disease outcome of Fcγ−/− mice was observed using 
infections with L. pifanoi or L. major (44, 49). However, the 
mice used were on a BALB/c background and, thus, are not 
comparable to those used for this study. Data generated with 
Leishmania-resistant mice might be more physiologically rel-
evant in a clinical setting because the course of disease in, for 
example, C57BL/6 mice more closely mimics L. major infec-
tions of humans.
In summary, we propose that the two predominant APCs 
in skin, MΦ and DCs, are sequentially engaged via diff  erent 
pathogen recognition receptors as cutaneous leishmaniasis 
evolves. Although in the initial “silent” phase, L. major pro-
mastigotes are primarily phagocytosed by resident MΦ via 
CR3, FcγR and DCs become critically important in estab-
lished infections. IgG-mediated uptake of L. major by DCs 
leads to IL-12 production and priming of Th1/Tc1 cells, 
both of which are required for effi   cient parasite killing by le-
sional MΦ. In contrast, FcγR-mediated uptake of amasti-
gotes by MΦ induces counterregulatory IL-10 production. 
This may facilitate activation of regulatory T cells, which, in 
turn, promotes parasite persistence and maintenance of T cell 
memory (39, 50). The balance between CR3 and FcγR-
triggered anti- and proinfl  ammatory mechanisms involving 
MΦ and DCs is critical for disease outcome. The unexpected 
identifi  cation of immune IgG production as a prerequisite for 
effi   cient cross-priming of Leishmania-specifi  c Th1/Tc1 cells 
is intriguing. In future experiments it will be important to as-
sess the T cell dependence of Leishmania-reactive antibody 
production, and to identify the APCs that are involved in 
B cell and, if relevant, Th priming.
MATERIALS AND METHODS
Animals. 6–8-wk-old BALB/c and C57BL/6 mice were purchased from 
the Central Animal Facility of the University of Mainz. CD18−/− mice (51) 
on a mixed C57BL/6J and 129/SV background were provided by K. Scharf-
fetter-Kochaneck (Department of Dermatology, University of Ulm, Ulm, 
Germany). FcγRII−/− mice (52) were obtained from H. Mossmann (Max 
Planck-Institut für Immunbiologie, Freiburg, Germany). Mice defi  cient for 
FcγRIII (53) and FcγRI (54) as well as FcγRI/III double defi  cient mice 
(all C57BL/6 background) were provided by S. Verbeek. C57BL/6 Fcγ−/− 
were obtained from T. Saito (RIKEN Research Center for Allergy and Im-
munology, Yokohama, Japan) (55) or from Taconic. B cell–defi  cient mice 
(C57BL/6 SCID, μMT, JHT) were gifts from M. Neurath, K. Steinbrink, 
and A. Waisman (all from University of Mainz, Mainz, Germany). All ani-
mals were housed in accordance with institutional and federal guidelines. All 
experiments were undertaken with approved license from the Animal Care 
and Use Committee of the Region Rheinland-Pfalz.
Cells. Infl   ammatory skin-derived MΦ (MΦ) were elicited by subcuta-
neous injection of polyacrylamide beads and enriched to homogeneity (7). 
BMDCs were generated in GM-CSF– and IL-4–containing media (56) and 
harvested on day 6 of cell culture. The characteristics of the cell populations 
were assessed by fl  ow cytometry using relevant surface markers. The follow-
ing antibodies were used: anti–I-Ab,d/I-Ed (2G9), anti-CD11b (M1/70), 
anti-CD11c (HL3), anti-CD40 (3/23), anti-CD54 (3E2), anti-CD80 
(1G10), anti-CD86 (GL1) (all from BD Biosciences/Becton Dickinson), 
anti-F4/80 (Serotec), and respective isotype control mAb.
Parasites. Metacyclic promastigotes or amastigotes of L. major clone VI 
(MHOM/IL/80/Friedlin) were prepared as described previously (25, 57). 
Amastigotes were prepared from infected footpads of BALB/c or C57BL/6 
mice, or mice genetically defi  cient in B cells (μMT, SCID) to obtain para-
sites devoid of Ig. Isolated parasites were opsonized with 5% NMS or serum 
from 6 wk–infected BALB/c or C57BL/6 mice (immune serum, IS) for 10 
min (37°C) and washed before in vitro or in vivo infections. Parasites were 
stained for surface-associated Ig using isotype-specifi  c secondary antibodies 
reactive with mouse Ig: anti-IgM (Serotec), anti-IgG1 (A85-1), and anti-
IgG2a/b (R2-40, all from BD Biosciences). After staining, parasites were 
washed with PBS/2% BSA, fi  xed, and analyzed by fl  ow cytometry. Anti-
Leishmania IgG was prepared from pooled sera of ≥5–6-wk L. major–infected 
BALB/c mice using protein G columns (Pierce Chemical Co.) following the 
manufacturer’s protocol. Sera were stored at −20°C before IgG purifi  cation. 
Purifi  ed IgG was stored at 4°C (0.8 mg/ml) in PBS before use.
Phagocytosis and inhibition studies. Isolated cells were subcultured in 
medium (RPMI 1640/5% FCS) at 2 × 105/ml and parasites were added at 
the parasite/cell ratios indicated. In some experiments, cells were preincu-
bated for 60 min with mannan (Sigma-Aldrich, 1 and 5 mg/ml), anti-
CD11b, anti-CD16/32, anti-CD205, or control rat IgG (all at 50 μg/ml, all 
from BD Biosciences). Cells were harvested after several hours and cytospins 
were prepared. Diff  Quick-stained cells were analyzed for the presence of in-
tra- and extracellular parasites. At least 200 cells were counted per sample. 
Supernatants from parasite/cell cocultures were collected and assayed for the 
presence of IL-12p40 or IL-10 by ELISA (BD Biosciences).
Assessment of B cell and DC infi   ltration and function in vivo. 
Groups of ≥5 C57BL/6 mice were infected intradermally in ear skin with 
1,000 L. major promastigotes. At several time points, ears were harvested and 
the number of B cells and DCs that had accumulated at the site of infection 
was determined (3). In brief, ears were incubated with 2 mg/ml Liberase 
(Boehringer Ingelheim). After 2 h, cells were dissociated mechanically and 
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fl  ow cytometry. In addition, serum from infected mice was obtained at sev-
eral time points and stored at −20°C.
Leishmania-specifi  c IgG in serum was quantifi  ed by ELISA. Flat-bottom 
96-well plates (Nunc) were coated overnight with 0.5 mg/100 μl of soluble 
freeze-thaw Leishmania lysate (SLA), blocked for 1 h with PBS/2% BSA/0.05% 
Tween 20, and incubated for 2 h with dilutions of sera or reference standard 
anti-Leishmania IgG (prepared from pooled sera of immune infected mice). 
Subsequently, biotinylated goat anti–mouse IgG (Caltag) was added (125 
ng/ml) for 2 h at 20°C. ELISA plates were developed using commercially 
available ELISA kit components (BD Biosciences) and reaction products 
were quantifi  ed spectrophotometrically.
In vivo infections using IgG-opsonized parasites and B cell– or Fc𝗄-
defi  cient mice. C57BL/6, μMT, JHT, or Fcγ−/− mice were infected intra-
dermally with 103 metacyclic L. major promastigotes. In some experiments, 
parasites were opsonized for 10 min with either NMS or IS and washed. Le-
sion development was assessed weekly in three dimensions using a caliper, 
and lesional volumes are reported (in mm3) as ellipsoids [(a/2 × b/2 × c/2) 
×4/3π]. Organisms present in lesional tissue were enumerated using limit-
ing dilution assays (57). For measurement of cytokine production, 106 retro-
auricular LN cells/200 μl were added to 96-well plates in the presence of 
SLA (25 μg/ml). Antigen-specifi  c IFN-γ and IL-4 production was deter-
mined after 48 h using ELISA (R&D Systems).
At several time points, ears were harvested and infl  ammatory cells iso-
lated using Liberase and mechanical disruption (3). The cells were counted 
and the frequencies of CD11c+ DC were determined using fl  ow cytometry. 
CD11c+ cells were enriched to >98% purity using a high speed cell sorter 
(FACS Vantage SE System, Becton Dickinson) and cytospins were analyzed 
by light microscopy to estimate the number of infected DCs/ear.
The frequency of daughter cells of proliferating antigen-reactive com-
pared with nonproliferating LN T cells was estimated using fl  ow cytometry 
(58–60). 6 wk after infection, LN cells were harvested and 5 × 106 cells/ml 
were labeled with 1 μM CFSE (Invitrogen). LN cells were subsequently 
plated at 106/200 μl media in a 96-well U-bottom plate and left untreated 
or stimulated with SEB (10 μg/ml; Sigma-Aldrich), or SLA (61). After 5 d, 
proliferation was determined using fl  ow cytometry. T cells were selected 
for analysis using mAbs against CD4 (L3T4, RM4-5), CD8 (Ly2, 53–6.7), 
or isotype control mAb (all from BD Biosciences). For each mouse, the 
  percentage of Leishmania-reactive cells compared with nonproliferating cells 
was calculated.
Statistics. Statistical analysis was performed using the unpaired Student’s 
t test.
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